Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04708015 · ClinicalTrials.gov registry record

Retrospective Study of Glucose Monitoring for Glycemic Control in Patients With GSDIa

A clinical trial, sponsored by Ultragenyx Pharmaceutical.

Completed
Registry status
15
Enrollment target

NCT04708015: Completed study, sponsored by Ultragenyx Pharmaceutical.

NCT04708015 is a clinical trial that has completed, run by Ultragenyx Pharmaceutical. The registered enrollment target is 15 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04708015 has completed, sponsored by Ultragenyx Pharmaceutical.

COMPLETED
Registry status
15 participants
Enrollment target

Study Summary

The primary objective of this study is to assess the percentage of time patients were in normal glucose control.

Interventions

  • OTHER No Intervention

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2020-11-05
Est. Completion 2022-03-04
Ultragenyx Pharmaceutical

52 total trials

What the finished NCT04708015 record still lists

NCT04708015 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 15 participants, a relatively small participant target.

The record links to 0 conditions, and to 1 intervention - of which No Intervention is the first listed.

NCT04708015 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04708015 about?

NCT04708015 is a clinical study titled "Retrospective Study of Glucose Monitoring for Glycemic Control in Patients With GSDIa". The primary objective of this study is to assess the percentage of time patients were in normal glucose control.

What is the current status of trial NCT04708015?

This trial is currently completed. The enrollment target is 15 participants. The study started on 2020-11-05. Estimated completion is 2022-03-04.

What interventions are being tested in trial NCT04708015?

The interventions under investigation include: No Intervention (OTHER).

Who is sponsoring clinical trial NCT04708015?

This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01889381 · 15 participants · Phase 2

    Human Craniomaxillofacial Allotransplantation

  • NCT02530073 · 15 participants · NA

    Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH

  • NCT02535936 · 15 participants · NA

    Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy

  • NCT02918474 · 15 participants · NA

    Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04708015, the US trial registry maintained by the National Library of Medicine. NCT04708015 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.